Advertisement


Saad Z. Usmani, MD: In My Experience Question 1

COVID-19 and Cancer Care

Advertisement

As a result of COVID-19, has your decision model for front-line therapy changed for patients with multiple myeloma who are either transplant-eligible or ineligible?

Recorded April 24, 2020.



Related Videos

COVID-19
Global Cancer Care
Skin Cancer

Paolo A. Ascierto, MD, on Cancer Treatment During the COVID-19 Pandemic: The View From Southern Italy

Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori in Naples, Italy, talks about minimizing risks for patients with cancer, prioritizing surgery and other treatments for...

Leukemia
COVID-19

Laura C. Michaelis, MD: In My Experience Question 1

How has the COVID-19 pandemic changed your approach to the selection of tyrosine kinase inhibitors for the treatment of patients with chronic myeloid leukemia?

Recorded Ap...

Leukemia
COVID-19

Laura C. Michaelis, MD: In My Experience Question 4

At this time, would you consider pausing therapy—specifically signaling inhibitors and/or monoclonal antibodies—in patients with chronic lymphocytic leukemia?

Recorded April 24,...

Multiple Myeloma
COVID-19

Saad Z. Usmani, MD: In My Experience Question 3

Because of the COVID-19 pandemic, has your management strategy changed for post-transplant consolidation and maintenance therapy in patients with multiple myeloma?

Recorde...

COVID-19

Mikkael A. Sekeres, MD, on Cancer Treatment in the Age of COVID-19: Personal Observations

Mikkael A. Sekeres, MD, of the Cleveland Clinic, talks about the ways in which social distancing and viral fears have affected the way he delivers treatment for his patients,...

Advertisement

Advertisement



Advertisement